DK0728018T3 - Nye enzymer og prodrugs til ADEPT - Google Patents

Nye enzymer og prodrugs til ADEPT

Info

Publication number
DK0728018T3
DK0728018T3 DK95900827T DK95900827T DK0728018T3 DK 0728018 T3 DK0728018 T3 DK 0728018T3 DK 95900827 T DK95900827 T DK 95900827T DK 95900827 T DK95900827 T DK 95900827T DK 0728018 T3 DK0728018 T3 DK 0728018T3
Authority
DK
Denmark
Prior art keywords
adept
prodrugs
enzymes
new enzymes
nucleic acid
Prior art date
Application number
DK95900827T
Other languages
Danish (da)
English (en)
Inventor
Gary Keith Smith
Michael Cory
Todd Andrew Blumenkopf
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Found filed Critical Wellcome Found
Application granted granted Critical
Publication of DK0728018T3 publication Critical patent/DK0728018T3/da

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicinal Preparation (AREA)
DK95900827T 1993-11-12 1994-11-11 Nye enzymer og prodrugs til ADEPT DK0728018T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939323429A GB9323429D0 (en) 1993-11-12 1993-11-12 Therapy
PCT/GB1994/002483 WO1995013095A2 (en) 1993-11-12 1994-11-11 Therapy

Publications (1)

Publication Number Publication Date
DK0728018T3 true DK0728018T3 (da) 2003-11-24

Family

ID=10745113

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95900827T DK0728018T3 (da) 1993-11-12 1994-11-11 Nye enzymer og prodrugs til ADEPT

Country Status (15)

Country Link
US (2) US6140100A (de)
EP (1) EP0728018B1 (de)
JP (1) JPH09507834A (de)
AT (1) ATE246516T1 (de)
AU (1) AU688412B2 (de)
CA (1) CA2176024A1 (de)
DE (1) DE69433015T2 (de)
DK (1) DK0728018T3 (de)
ES (1) ES2204935T3 (de)
GB (1) GB9323429D0 (de)
IL (1) IL111601A0 (de)
MY (1) MY114140A (de)
NZ (1) NZ276137A (de)
WO (1) WO1995013095A2 (de)
ZA (1) ZA948987B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
DE69527805T2 (de) * 1994-12-23 2003-04-24 Astrazeneca Ab, Soedertaelje Chemische mittel
GB2309033B (en) * 1994-12-23 1999-06-02 Zeneca Ltd Chemical compounds
AU707689B2 (en) * 1995-08-16 1999-07-15 Astrazeneca Ab Mutated Carboxypeptidase B enzyme conjugated to a tumour targeted antibody for use in Antibody Directed Enzyme Prodrug Therapy
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
AU2205499A (en) * 1997-12-31 1999-07-19 Incyte Pharmaceuticals, Inc. Human regulatory proteins
WO2001034779A2 (en) 1999-11-12 2001-05-17 Lexicon Genetics Incorporated Human proteins with homology to carboxypeptidases and polynucleotides encoding the same
EP1343531A2 (de) * 2000-12-21 2003-09-17 McGILL UNIVERSITY Konjugate von antikörpern und antikrebsmitteln
ATE417606T1 (de) 2001-09-14 2009-01-15 Glaxo Group Ltd Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
US7572442B2 (en) 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Selected antibody compositions for binding to aminophospholipids
US20110002978A1 (en) * 2003-06-17 2011-01-06 Harrison Roger G Enzyme prodrug cancer therapy selectively targeted to tumor cells or tumor vasculature and methods of production and use thereof
EP1725250A2 (de) * 2004-02-18 2006-11-29 Frutarom Ltd. Verfahren zur herstellung von peptid-oligonucleotid-konjugaten
EP1794294B1 (de) * 2004-09-27 2011-07-20 Sanofi-Aventis Deutschland GmbH Rekombinante carboxypeptidase b
CA2586334A1 (en) * 2004-11-16 2006-06-08 Neurochem (International) Limited Compounds for the treatment of cns and amyloid associated diseases
MX2010005104A (es) 2007-11-09 2010-08-04 Peregrine Pharmaceuticals Inc Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
PL2491788T3 (pl) 2011-02-25 2016-07-29 Kraft Foods R & D Inc Wyrób spożywczy z formowanym korpusem
US9340504B2 (en) * 2013-11-21 2016-05-17 Purdue Pharma L.P. Pyridine and piperidine derivatives as novel sodium channel blockers
CN105916836B (zh) 2013-12-17 2021-02-09 斯特拉制药公司 2-氟-4-二羟硼基-l-苯丙氨酸的制造方法及其前体
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
WO2020032951A1 (en) 2018-08-09 2020-02-13 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
WO2022272307A1 (en) * 2021-06-24 2022-12-29 Lycia Therapeutics, Inc. Bifunctional folate receptor binding compounds
JP2024524614A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス, インコーポレイテッド Asgpr細胞表面受容体結合化合物及びコンジュゲート

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
AU648015B2 (en) * 1989-01-23 1994-04-14 Akzo N.V. Site specific in-vivo activation of therapeutic drugs
US5433955A (en) 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
FI94362C (fi) * 1989-10-20 1995-08-25 Squibb Bristol Myers Co Oleellisesti puhdistettu sulfataasi, menetelmä sen valmistamiseksi ja sitä tuottava Streptomyces-kanta
GB9200415D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Inactivation of cytotoxic drugs
US6187579B1 (en) * 1993-10-28 2001-02-13 Carlsberg A/S Customized proteases
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5985627A (en) * 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase

Also Published As

Publication number Publication date
US6140100A (en) 2000-10-31
DE69433015T2 (de) 2004-06-09
ES2204935T3 (es) 2004-05-01
WO1995013095A2 (en) 1995-05-18
AU8148894A (en) 1995-05-29
ZA948987B (en) 1996-05-13
AU688412B2 (en) 1998-03-12
EP0728018A1 (de) 1996-08-28
US6319702B1 (en) 2001-11-20
JPH09507834A (ja) 1997-08-12
MY114140A (en) 2002-08-30
DE69433015D1 (de) 2003-09-11
CA2176024A1 (en) 1995-05-18
EP0728018B1 (de) 2003-08-06
ATE246516T1 (de) 2003-08-15
IL111601A0 (en) 1995-01-24
NZ276137A (en) 1998-04-27
GB9323429D0 (en) 1994-01-05
WO1995013095A3 (en) 1995-07-13

Similar Documents

Publication Publication Date Title
ATE246516T1 (de) Neue enzyme und prodrugs für adept
PT101297A (pt) Factores mitogenicos gliais, sua preparacao e utilizacao
ATE199937T1 (de) Gensequenzen kodierend für flavonoid- stoffwechselwegenzyme und deren verwendung
DE69535543D1 (de) Für enzyme, die die fähigkeit besitzen lineare alpha 1,4-glucane in pflanzen, pilzen und mikroorganismen zu synthesieren, kodierende dna sequenzen
DK1151085T3 (da) Nukleinsyremolekyler, der koder for alternansucrase
NO20021931L (no) L-pantolacton-hydrolase og en fremgangsmåte for fremstilling av D-pantolacton
GEP20032871B (en) Regulation of Quinolate Phosphoribosyl Transferase Expression
CA2315274A1 (en) Polypeptides having aminopeptidase activity and nucleic acids encoding same
DE69521331D1 (de) Nukleinsäure-einbringungssystem
HU9502920D0 (en) New bacillus thuringiensis strains and their insecticidal proteins
BG101892A (en) Sugar-modified cytostatics
DE69331484D1 (de) N-Acetylglucosaminyl-Transferase, dafür kodierendes Gen, entsprechende Vektoren und transformierte Wirte und Herstellungsverfahren dafür
NO910982L (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
AU7489098A (en) Polypeptides having aminopeptidase activity and nucleic acids encoding same
FR2710074B1 (fr) Gène GRB3-3, ses variants et leurs utilisations.
IT1260153B (it) Individuazione di un frammento di dna codificante l'enzima acido ialuronico sintetasi (has) e della sua sequenza nucleotidica
AU1682092A (en) Production of plants resistant to attacks of sclerotinia sclerotiorum by introducing a gene coding for an oxalate oxidase
BG102355A (bg) Метод за стимулиране на клетъчно медиирани имунниотговори чрез насочване на определена генетична последователност
ES8206621A1 (es) Procedimiento para la obtencion de isomaltulosa a partir de sacarosa
DK1005532T3 (da) Isolerede nukleinsyremolekyler kodende for SSX familiemedlemmer og anvendelser deraf
DE69631899D1 (de) Xylanasen, für diese kodierende gene und anwendungen derselben
AU1577799A (en) Nucleotide sequences encoding the tomato light hypersensitive phenotype, encodedproteins and uses thereof
MX9709459A (es) Metodo para prolongar la expresion de un gen de interes usando moleculas de ctla4 solubles.
MX9709505A (es) Metodo para transferir al menos dos unidades de sacarido con una poliglicoslitransferasa.